Literature DB >> 4078051

Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases.

R Ruiz-Maldonado.   

Abstract

Sixty patients with acute disseminated epidermal necrosis (ADEN) were hospitalized and carefully studied. They included thirty-nine patients with drug-associated Stevens-Johnson syndrome, five patients with drug-associated Lyell's syndrome, and sixteen patients with transitional ADEN. On the basis of growing evidence of an association between erythema multiforme major and drugs and between Lyell's syndrome and drugs, and because of the existence of transitional cases, a unitary hypothesis for this group of cases is proposed. Considering the lack of precise definitions and the confusing current terminology, we define and propose the following terms: ADEN type 1 for drug-associated Stevens-Johnson syndrome, ADEN type 2 for drug-associated transitional cases, and ADEN type 3 for drug-associated toxic epidermal necrolysis, or Lyell's syndrome. The most frequent underlying diseases in our patients were seizures, and the most frequently suspected cause of ADEN was the use of anticonvulsants. All our patients were treated with supportive therapy; none received corticosteroids. The general mortality rate was 15%. The recognition of ADEN type 2 (transitional) has important prognostic and therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4078051     DOI: 10.1016/s0190-9622(85)70207-1

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  14 in total

Review 1.  Idiosyncratic drug reactions: a mechanistic evaluation of risk factors.

Authors:  B K Park; M Pirmohamed; N R Kitteringham
Journal:  Br J Clin Pharmacol       Date:  1992-11       Impact factor: 4.335

2.  Antecedent Drug Exposure Aetiology and Management Protocols in Steven-Johnson Syndrome and Toxic Epidermal Necrolysis, A Hospital Based Prospective Study.

Authors:  Samina Farhat; Muddasir Banday; Iffat Hassan
Journal:  J Clin Diagn Res       Date:  2016-01-01

Review 3.  Clinical features and management of severe dermatological reactions to drugs.

Authors:  M C Raviglione; A Pablos-Mendez; R Battan
Journal:  Drug Saf       Date:  1990 Jan-Feb       Impact factor: 5.606

Review 4.  Drug-induced severe skin reactions. Incidence, management and prevention.

Authors:  P Wolkenstein; J Revuz
Journal:  Drug Saf       Date:  1995-07       Impact factor: 5.606

5.  How frequent are notified severe cutaneous adverse reactions to Fansidar?

Authors:  D Stürchler; M L Mittelholzer; L Kerr
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

Review 6.  Allergic emergencies encountered by the dermatologist. Severe cutaneous adverse drug reactions.

Authors:  P Wolkenstein; J Revuz
Journal:  Clin Rev Allergy Immunol       Date:  1999       Impact factor: 10.817

7.  Toxic epidermal necrolysis associated with severe cytomegalovirus infection in a patient on regular hemodialysis.

Authors:  Dina Khalaf; Bassem Toema; Nidal Dabbour; Fathi Jehani
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-01-14       Impact factor: 2.576

8.  Vesicobullous disorders of female genitalia.

Authors:  Taru Garg; Saurabh Mittal
Journal:  Indian J Sex Transm Dis AIDS       Date:  2012-01

Review 9.  Bullous Drug Reactions.

Authors:  Maja Mockenhaupt
Journal:  Acta Derm Venereol       Date:  2020-02-12       Impact factor: 3.875

10.  Fluconazole induced toxic epidermal necrolysis: a case report.

Authors:  Uchenna R Ofoma; Edward K Chapnick
Journal:  Cases J       Date:  2009-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.